Spotlight Surgical

Spotlight Medical is a precision medicine firm operating at the intersection of artificial intelligence and oncology. Established in 2024 and headquartered in Paris, France, the company is focused on developing advanced prognosis tests to guide physicians in selecting optimal cancer treatments. The core of its business is a platform that leverages AI algorithms to analyze vast sets of patient data, aiming to provide insights that prevent both over-treatment and under-treatment of cancer patients.

The company was founded by CEO Sylvain Berlemont. From its inception, Spotlight Medical has garnered significant support from the medical community, backed by internationally recognized cancer centers, the Institut Curie and Gustave Roussy. This collaboration provides a strong clinical foundation for its technology development. The business model is centered on the commercialization of these AI-driven clinical tests, which will be offered to healthcare providers and cancer treatment centers.

In a significant milestone for the young company, Spotlight Medical secured €6.2 million in a seed funding round in July 2024. The investment was co-led by venture capital firms Kurma Partners and Heal Capital. This infusion of capital is earmarked to advance its first prognosis test into clinical use, a critical step toward commercialization and making a tangible impact on patient outcomes. The company’s approach seeks to provide a concrete AI-based solution to enhance the precision of cancer therapy.

Keywords: precision medicine, oncology, AI in healthcare, cancer diagnostics, prognosis tests, clinical decision support, patient data analysis, cancer treatment selection, medical technology, digital health, Paris startup, Institut Curie, Gustave Roussy, Sylvain Berlemont, Kurma Partners, Heal Capital, oncology AI, personalized medicine, cancer care, health tech